Eli Lilly to Sell Zepbound and Foundayo Directly on Hims & Hers

Direct answer

Eli Lilly, the maker of the weight-loss drugs Zepbound and Foundayo, has struck a deal with telehealth company Hims & Hers. From now on, patients who get a prescription on the Hims & Hers platform can buy the FDA-approved medicines there directly, without leaving the site. The self-pay prices start at $149 a month for the Foundayo pill and $299 a month for the Zepbound injection, the same prices Lilly charges through its own LillyDirect platform.

What happened

Eli Lilly and Hims & Hers announced the agreement on Friday, November 6, 2026. Under the deal, a patient completes a consultation with a licensed provider on the Hims & Hers platform, and if the provider prescribes one of the medicines, it is shipped to the patient’s home. The whole journey happens in one place.

Before this deal, a Hims & Hers patient who wanted a Lilly drug had to leave the site and go to LillyDirect, Lilly’s own direct-to-consumer platform, to complete the purchase. That extra step is now gone.

The deal covers Zepbound (tirzepatide), Lilly’s weekly injectable weight-loss drug, and Foundayo (orforglipron), its newer once-daily weight-loss pill. Foundayo was approved by the US Food and Drug Administration on April 1, 2026.

As part of the agreement, Hims & Hers said it has never offered compounded copies of Lilly’s weight-loss medicines and committed not to do so in the future. Compounded copies are custom-mixed versions of a drug that are not approved by the FDA, and they have been a flashpoint in the weight-loss market.

The market liked the news for Hims & Hers. Its shares rose more than 7% in premarket trading on Friday, according to Reuters. The companies did not disclose the financial terms of the deal.

Why it matters for beginners

This deal is about distribution, which is simply how a product reaches its buyers. Lilly already makes the best-selling weight-loss drugs in the world. Zepbound brought in $5.35 billion in the third quarter of 2026 alone, up 49% from a year earlier, and $14.44 billion so far this year. Foundayo added $184 million in the quarter. The problem Lilly is solving here is not demand, it is making it easier for people to buy.

Hims & Hers gives Lilly a ready-made storefront with millions of subscribers. Patients can consult, get a prescription, and order in one visit instead of jumping between websites. Fewer steps usually means more completed purchases, and that is why this kind of partnership matters to investors.

It also puts Lilly on equal footing with its main rival. Novo Nordisk, the maker of Wegovy and Ozempic, has been selling its weight-loss drugs through Hims & Hers since March 2026. You can read about its latest results in our post on Novo Nordisk beating expectations as Wegovy sales lifted Q3 results. Now both of the big branded weight-loss drug makers sell through the same telehealth platform.

The prices matter too. At $149 a month for Foundayo and $299 a month for Zepbound, these are cash prices paid by the patient, outside their insurance. That makes the drugs reachable for people whose insurance does not cover weight-loss treatment, but it is still a large monthly cost for most households.

What to watch next

• Whether Hims & Hers reports a jump in weight-loss subscribers and sales in its next quarterly results.
• How Novo Nordisk responds, now that both rivals share the same telehealth storefront.
• Whether regulators or insurers push back on cash-pay telehealth sales of weight-loss drugs.
• Lilly’s next earnings report on February 3, 2027, for the first numbers on how this channel is performing.

FAQ

What are Zepbound and Foundayo?

Zepbound is Eli Lilly’s weekly injectable medicine for chronic weight management, and Foundayo is its once-daily oral pill for the same use. Both are approved by the FDA and sold at set self-pay prices.

How much will the medicines cost on Hims & Hers?

Self-pay pricing starts at $149 a month for Foundayo and $299 a month for Zepbound, matching the prices Lilly charges through its own LillyDirect platform. These are cash prices, paid by the patient without insurance.

What is a compounded copy of a drug?

A compounded copy is a custom-mixed version of a drug made by a pharmacy, rather than the FDA-approved product from the original maker. Hims & Hers has committed not to offer compounded copies of Lilly’s medicines.

Why did Hims & Hers shares rise on the news?

Investors saw the deal as a win for Hims & Hers: it now sells branded weight-loss drugs from both Lilly and Novo Nordisk, the two dominant makers, directly on its platform. Its shares rose more than 7% in premarket trading on November 6, according to Reuters.

Sources

Reuters, “Lilly to sell obesity drugs directly on Hims & Hers site,” November 6, 2026. https://www.reuters.com/legal/litigation/lilly-sell-obesity-drugs-directly-hims-hers-site-2026-11-06/
Eli Lilly and Company, “Lilly and Hims & Hers expand access to FDA-approved Lilly medicines,” November 6, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines

This article is for general information and education only. It is not legal or financial advice.